These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 22465563)

  • 1. Introduction to the pulmonary research group's symposium: Preclinical research in COPD and pulmonary fibrosis.
    Williams CM; Lundblad LK
    Pulm Pharmacol Ther; 2012 Aug; 25(4):255-6. PubMed ID: 22465563
    [No Abstract]   [Full Text] [Related]  

  • 2. Abnormal lung aging in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis.
    Faner R; Rojas M; Macnee W; Agustí A
    Am J Respir Crit Care Med; 2012 Aug; 186(4):306-13. PubMed ID: 22582162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Commonalities between the pro-fibrotic mechanisms in COPD and IPF.
    Murray LA
    Pulm Pharmacol Ther; 2012 Aug; 25(4):276-80. PubMed ID: 21983244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical staining for transcription factor MafB in alveolar macrophages is correlated with spirometric measures of airflow limitation in smokers.
    Sato M; Shibata Y; Kimura T; Yamauchi K; Abe S; Inoue S; Kishi H; Oizumi H; Kubota I
    Respirology; 2011 Jan; 16(1):124-30. PubMed ID: 20969674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of nasal high flow on ventilation in volunteers, COPD and idiopathic pulmonary fibrosis patients.
    Bräunlich J; Beyer D; Mai D; Hammerschmidt S; Seyfarth HJ; Wirtz H
    Respiration; 2013; 85(4):319-25. PubMed ID: 23128844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of peroxisome proliferator-activated receptor-γ ligands on in vitro and in vivo models of COPD.
    Lea S; Plumb J; Metcalfe H; Spicer D; Woodman P; Fox JC; Singh D
    Eur Respir J; 2014 Feb; 43(2):409-20. PubMed ID: 23794466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-regulated NF-E2-related factor 2 in pulmonary macrophages of aged smokers and patients with chronic obstructive pulmonary disease.
    Suzuki M; Betsuyaku T; Ito Y; Nagai K; Nasuhara Y; Kaga K; Kondo S; Nishimura M
    Am J Respir Cell Mol Biol; 2008 Dec; 39(6):673-82. PubMed ID: 18566336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parenchymal trafficking of pleural mesothelial cells in idiopathic pulmonary fibrosis.
    Mubarak KK; Montes-Worboys A; Regev D; Nasreen N; Mohammed KA; Faruqi I; Hensel E; Baz MA; Akindipe OA; Fernandez-Bussy S; Nathan SD; Antony VB
    Eur Respir J; 2012 Jan; 39(1):133-40. PubMed ID: 21737551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Premature lung aging and cellular senescence in the pathogenesis of idiopathic pulmonary fibrosis and COPD/emphysema.
    Chilosi M; Carloni A; Rossi A; Poletti V
    Transl Res; 2013 Sep; 162(3):156-73. PubMed ID: 23831269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced deposition of low-molecular-weight hyaluronan in lungs of cigarette smoke-exposed mice.
    Bracke KR; Dentener MA; Papakonstantinou E; Vernooy JH; Demoor T; Pauwels NS; Cleutjens J; van Suylen RJ; Joos GF; Brusselle GG; Wouters EF
    Am J Respir Cell Mol Biol; 2010 Jun; 42(6):753-61. PubMed ID: 19675307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Animal models of COPD: Barriers, successes, and challenges.
    Wright JL; Churg A
    Pulm Pharmacol Ther; 2008 Oct; 21(5):696-8. PubMed ID: 18325803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different inflammatory cell pattern and macrophage phenotype in chronic obstructive pulmonary disease patients, smokers and non-smokers.
    Löfdahl JM; Wahlström J; Sköld CM
    Clin Exp Immunol; 2006 Sep; 145(3):428-37. PubMed ID: 16907910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modelling COPD in mice.
    Vlahos R; Bozinovski S; Gualano RC; Ernst M; Anderson GP
    Pulm Pharmacol Ther; 2006; 19(1):12-7. PubMed ID: 16286233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Animal models of chronic obstructive pulmonary disease.
    Fricker M; Deane A; Hansbro PM
    Expert Opin Drug Discov; 2014 Jun; 9(6):629-45. PubMed ID: 24754714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased histone deacetylase activity in chronic obstructive pulmonary disease.
    Ito K; Ito M; Elliott WM; Cosio B; Caramori G; Kon OM; Barczyk A; Hayashi S; Adcock IM; Hogg JC; Barnes PJ
    N Engl J Med; 2005 May; 352(19):1967-76. PubMed ID: 15888697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Airway endothelial dysfunction in asthma and chronic obstructive pulmonary disease: a challenge for future research.
    Wanner A; Mendes ES
    Am J Respir Crit Care Med; 2010 Dec; 182(11):1344-51. PubMed ID: 20709816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NRF2 targeting: a promising therapeutic strategy in chronic obstructive pulmonary disease.
    Boutten A; Goven D; Artaud-Macari E; Boczkowski J; Bonay M
    Trends Mol Med; 2011 Jul; 17(7):363-71. PubMed ID: 21459041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of inflammatory responses in large and small airways in smokers with and without chronic obstructive pulmonary disease.
    Isajevs S; Taivans I; Svirina D; Strazda G; Kopeika U
    Respiration; 2011; 81(5):362-71. PubMed ID: 21228544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction.
    Chung KF; Adcock IM
    Eur Respir J; 2008 Jun; 31(6):1334-56. PubMed ID: 18515558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innate immunity proteins in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis.
    Tsoumakidou M; Bouloukaki I; Thimaki K; Tzanakis N; Siafakas NM
    Exp Lung Res; 2010 Aug; 36(6):373-80. PubMed ID: 20653472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.